CASP3 and prostate carcinoma: The treatment of chronic myelogenous leukemia K562 cells (5), human prostate cancer PC-3 cells (20), melanoma cells (6) and osteosarcoma cells (21) with shikonin induced apoptosis through increased caspase-3 activity.